CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that a new patent has been issued by the U.S. Patent and Trademark Office (USPTO) relating to its tamper resistant, abuse-deterrent formulation platform. US Patent Number 7,399,488 contains claims that cover orally administrable compositions comprising Collegium’s proprietary micro-particle formulations. The formulations are designed to be more resistant to physical methods of tampering than currently available sustained release dosage forms. US Patent No. 7,399,488 will provide protection for DETERx™ and products incorporating the DETERx™ technology into the year 2025.
